MRD Reference Standard

Background

Minimal Residual Disease (MRD) refers to trace amounts of cancer cells that persist after treatment, often undetectable through conventional methods. Early MRD detection is crucial for assessing treatment efficacy, predicting relapse risks, and guiding personalized therapeutic strategies. To address the need for reliable MRD quantification, our MRD Reference Standards are developed to validate and calibrate next-generation sequencing (NGS) and PCR-based assays in clinical/research settings.

Key Features

• High Sensitivity & Accuracy: Simulates MRD levels as low as 0.005% , supporting ultra-sensitive detection.

• Comprehensive Mutations: Pre-defined panels cover common hematologic/oncologic biomarkers (e.g., BCR-ABL1, TP53, KRAS) for multi-target validation.

• Wide coverage: 30+ genes and 40+ sites,calibrate low-frequency and ultra-low-frequency loci.

• Rich mutation types： SNV/Insertion/Deletion/Fusion.

Applications

• Clinical Testing: Optimize MRD assay validation for leukemia, lymphoma, and solid tumors.

• Therapeutic Monitoring: Track residual disease dynamics during chemotherapy or CAR-T therapy.

• Prognostic Evaluation: Establish correlation between MRD status and patient survival outcomes.